Dr. Reddy’s Launches of OTC Store Brand Equivalent of Prilosec OTC Tablets in US Market

Dr. Reddy’s Laboratories Ltd. announced the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market as approved by the U.S. Food and Drug Administration (USFDA). OTC Omeprazole Delayed-Release Tablets, 20 mg, is a proton pump inhibitor used to treat frequent heartburn occurring two or more days per week in adults.

“This launch illustrates our continued commitment to the OTC business as well as the depth and breadth of our OTC portfolio,” says Milan Kalawadia, Vice President and Head, US OTC and Specialty Rx businesses, Dr. Reddy’s Laboratories. “We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers.”

The combined market of Prilosec OTC and private label omeprazole OTC products had U.S. retail sales of approximately USD 492 million for the most recent twelve months ending in October 2018 according to IRI. Dr. Reddy’s Omeprazole Delayed-Release Tablets, 20 mg, is available in 14 count bottles sold in cartons of 1, 2, or 3 bottles each. Each bottle contains one complete 14-day course of treatment. Use only as directed. – Medical Buyer Bureau